NERV (Minerva Neurosciences Corp) יתרות המזומנים של החברה

Minerva Neurosciences relies on external CDMO facilities for drug production to minimize manufacturing risks. The current cash position illustrates financial stability, while 0.08 reflects the latest metric value. Stable management aims to overcome FDA hurdles, and the non-cyclical demand for schizophrenia therapy makes the company's success dependent solely on regulatory decisions.
פילוחים אנליטיים ודוחות נתונים של חברת Minerva Neurosciences, Inc. (NERV)

To minimize fundamental risks, investors should divest from illiquid assets by analyzing the total volume of available cash and cash equivalents. This metric measures real financial stability, allowing the cash history of Minerva Neurosciences (NERV) to track the burn rate during the period of collecting additional clinical data for its schizophrenia drug. A downward trend on this chart signals the depletion of resources amid the suspension of new developments.